FDA blesses CellTrans' Lantidra, the first cell therapy for Type 1 diabetes

Thursday, the FDA signed off on CellTrans’ Lantidra (donislecel), the first cell therapy for Type 1 diabetes. The treatment, mined from deceased donor pancreatic cells, is for patients who are unable to achieve average blood glucose levels with daily insulin injections or with continuous infusion by way of a pump.